FXR Signaling in the Enterohepatic System

Overview

Journal Mol Cell Endocrinol

Specialties Cell Biology
Endocrinology
Molecular Biology

Date 2012 May 22

PMID 22609541

Citations 168

Authors

Tsutomu Matsubara

Fei Li

Frank J Gonzalez

Affiliations

Soon will be listed here.

Abstract

Enterohepatic circulation serves to capture bile acids and other steroid metabolites produced in the liver and secreted to the intestine, for reabsorption back into the circulation and reuptake to the liver. This process is under tight regulation by nuclear receptor signaling. Bile acids, produced from cholesterol, can alter gene expression in the liver and small intestine via activating the nuclear receptors farnesoid X receptor (FXR; NR1H4), pregnane X receptor (PXR; NR1I2), vitamin D receptor (VDR; NR1I1), G protein coupled receptor TGR5, and other cell signaling pathways (JNK1/2, AKT and ERK1/2). Among these controls, FXR is known to be a major bile acid-responsive ligand-activated transcription factor and a crucial control element for maintaining bile acid homeostasis. FXR has a high affinity for several major endogenous bile acids, notably cholic acid, deoxycholic acid, chenodeoxycholic acid, and lithocholic acid. By responding to excess bile acids, FXR is a bridge between the liver and small intestine to control bile acid levels and regulate bile acid synthesis and enterohepatic flow. FXR is highly expressed in the liver and gut, relative to other tissues, and contributes to the maintenance of cholesterol/bile acid homeostasis by regulating a variety of metabolic enzymes and transporters. FXR activation also affects lipid and glucose metabolism, and can influence drug metabolism.

Citing Articles

Microbial transformations of bile acids and their receptors in the regulation of metabolic dysfunction-associated steatotic liver disease.

Gao Y, Lin J, Ye C, Guo S, Jiang C Liver Res. 2025; 7(3):165-176.

PMID: 39958385 PMC: 11792070. DOI: 10.1016/j.livres.2023.09.002.

Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions.

Zhao Q, Wu J, Ding Y, Pang Y, Jiang C Life Metab. 2025; 2(6):load032.

PMID: 39872860 PMC: 11749371. DOI: 10.1093/lifemeta/load032.

Interplay of Oxidative Stress, Gut Microbiota, and Nicotine in Metabolic-Associated Steatotic Liver Disease (MASLD).

Mignini I, Galasso L, Piccirilli G, Calvez V, Termite F, Esposto G Antioxidants (Basel). 2025; 13(12.

PMID: 39765860 PMC: 11727446. DOI: 10.3390/antiox13121532.

Investigating the Effects of Dietary Bile Acids on Production Performance and Lipid Metabolism in Late-Phase Laying Hens.

Wang L, Fan K, Xing R, Yin J, Si X, Zhang H Animals (Basel). 2025; 14(24.

PMID: 39765458 PMC: 11672458. DOI: 10.3390/ani14243554.

Enhanced dynamic coupling in a nuclear receptor underlies ligand activity.

Yu T, Villalona P, Khan S, Mikeasky N, Meinert E, Magafas J J Biol Chem. 2024; 301(2):108081.

PMID: 39675705 PMC: 11783427. DOI: 10.1016/j.jbc.2024.108081.

References

Li T, Matozel M, Boehme S, Kong B, Nilsson L, Guo G . Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology. 2011; 53(3):996-1006. PMC: 3079544. DOI: 10.1002/hep.24107. View

Kir S, Beddow S, Samuel V, Miller P, Previs S, Suino-Powell K . FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011; 331(6024):1621-4. PMC: 3076083. DOI: 10.1126/science.1198363. View

Moschetta A, L Bookout A, Mangelsdorf D . Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 2004; 10(12):1352-8. DOI: 10.1038/nm1138. View

Lu Y, Heydel J, Li X, Bratton S, Lindblom T, Radominska-Pandya A . Lithocholic acid decreases expression of UGT2B7 in Caco-2 cells: a potential role for a negative farnesoid X receptor response element. Drug Metab Dispos. 2005; 33(7):937-46. PMC: 2652669. DOI: 10.1124/dmd.104.003061. View

Coppola C, Gosche J, Arrese M, Ancowitz B, Madsen J, Vanderhoof J . Molecular analysis of the adaptive response of intestinal bile acid transport after ileal resection in the rat. Gastroenterology. 1998; 115(5):1172-8. DOI: 10.1016/s0016-5085(98)70088-5. View

Strautnieks S, Bull L, Knisely A, Kocoshis S, Dahl N, Arnell H . A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 1998; 20(3):233-8. DOI: 10.1038/3034. View

Lu T, Makishima M, REPA J, Schoonjans K, Kerr T, Auwerx J . Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 2000; 6(3):507-15. DOI: 10.1016/s1097-2765(00)00050-2. View

Pircher P, Kitto J, Petrowski M, Tangirala R, Bischoff E, Schulman I . Farnesoid X receptor regulates bile acid-amino acid conjugation. J Biol Chem. 2003; 278(30):27703-11. DOI: 10.1074/jbc.M302128200. View

Hagenbuch B, Meier P . Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994; 93(3):1326-31. PMC: 294097. DOI: 10.1172/JCI117091. View

10.

Kir S, Kliewer S, Mangelsdorf D . Roles of FGF19 in liver metabolism. Cold Spring Harb Symp Quant Biol. 2011; 76:139-44. DOI: 10.1101/sqb.2011.76.010710. View

11.

Inagaki T, Moschetta A, Lee Y, Peng L, Zhao G, Downes M . Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006; 103(10):3920-5. PMC: 1450165. DOI: 10.1073/pnas.0509592103. View

12.

Kim I, Ahn S, Inagaki T, Choi M, Ito S, Guo G . Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res. 2007; 48(12):2664-72. DOI: 10.1194/jlr.M700330-JLR200. View

13.

Maran R, Thomas A, Roth M, Sheng Z, Esterly N, Pinson D . Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther. 2008; 328(2):469-77. PMC: 2682273. DOI: 10.1124/jpet.108.145409. View

14.

Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L . Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology. 2001; 33(3):633-46. DOI: 10.1053/jhep.2001.22646. View

15.

GROBER J, Zaghini I, Fujii H, Jones S, Kliewer S, Willson T . Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J Biol Chem. 1999; 274(42):29749-54. DOI: 10.1074/jbc.274.42.29749. View

16.

Vessey D, Crissey M, Zakim D . Kinetic studies on the enzymes conjugating bile acids with taurine and glycine in bovine liver. Biochem J. 1977; 163(1):181-3. PMC: 1164677. DOI: 10.1042/bj1630181. View

17.

Morelli A, Vignozzi L, Maggi M, Adorini L . Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. Biochim Biophys Acta. 2010; 1812(8):859-66. DOI: 10.1016/j.bbadis.2010.10.013. View

18.

Kato M . Intestinal first-pass metabolism of CYP3A4 substrates. Drug Metab Pharmacokinet. 2008; 23(2):87-94. DOI: 10.2133/dmpk.23.87. View

19.

Akwabi-Ameyaw A, Bass J, Caldwell R, Caravella J, Chen L, Creech K . Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Bioorg Med Chem Lett. 2008; 18(15):4339-43. DOI: 10.1016/j.bmcl.2008.06.073. View

20.

Maloney P, Parks D, Haffner C, Fivush A, Chandra G, Plunket K . Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem. 2000; 43(16):2971-4. DOI: 10.1021/jm0002127. View